The application lays the groundwork for the test to be added to the Medicare Benefit Schedule (MBS). Inclusion on the schedule would mean eligible patients receive a Medicare rebate for the PromarkerD test.
The Company is also pursuing Therapeutic Goods Administration (TGA) approval for PromarkerD, which is a parallel and independent process, and the Company will provide updates as and when events occur on this front.